JAMA Network
About The Study: In this study, semaglutide was associated with reduced opioid overdose risk in patients with comorbid type 2 diabetes and opioid use disorder, suggesting its potential therapeutic value for preventing overdoses. The results need validation from other data resources and study populations. Further research is warranted to investigate the underlying mechanisms and randomized clinical trials are necessary to corroborate the clinical effects on opioid use disorder.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
